Private Banking|Professional Solutions|Investment Management|Investment Banking|About us
Contact
Login
  • Solutions
  • Sectors
  • Careers
Jun 2014
ablynx
Joint Bookrunner
41.7 million
Accelerated Bookbuild Offering

Ablynx

Ablynx is a listed Belgian biotech focused on the discovery and development of innovative products for serious diseases, including inflammation, haematology and oncology

  • Ablynx placed 4,908,332 new shares to fund ongoing and future clinical trials
  • Kempen & Co acted as Joint Bookrunner and generated significant demand resulting in the upsizing of the deal from an initial €30m at launch to a total of €41.7m

Fully focused on your future

Private Banking
  • Offices
  • Entrepreneurs
  • Healthcare
  • Executives
  • Business professionals
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions
Investment Management
Investment Banking

© Van Lanschot Kempen NV 2024About usSecurity and fraud awarenessPrivacy & cookiesDisclaimer